Trial · NCT06462014
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants According to Geographic Region | Relugolix | South | 240 | Participants | |
| Number of Participants According to Geographic Region | Relugolix | West | 94 | Participants | |
| Number of Participants According to Geographic Region | Relugolix | Northeast | 93 | Participants | |
| Number of Participants According to Geographic Region | Relugolix | Midwest | 80 | Participants | |
| Number of Participants According to Index Year | Relugolix | 2020 | 0 | Participants | |
| Number of Participants According to Index Year | Relugolix | 2021 | 81 | Participants | |
| Number of Participants According to Index Year | Relugolix | 2022 | 203 | Participants | |
| Number of Participants According to Index Year | Relugolix | 2023 | 223 | Participants | |
| Time From First Observed Prostate Cancer Diagnosis Date to the Index Date | Relugolix | 55.8 | Standard Deviation 61.7 | Months | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Pain medication | 103 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Androgen receptor pathway inhibitor | 86 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Androgen deprivation therapy | 77 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Chronic oral corticosteroid use | 48 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Non-steroidal anti-androgen | 46 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Radiotherapy | 7 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Olaparib | 3 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Prostatectomy | 3 | Participants | |
| Number of Participants According to Type of Previous Treatments Received | Relugolix | Chemotherapy | 2 | Participants | |
| Number of Participants According to Metastasis Status | Relugolix | Metastatic prostate cancer | 169 | Participants | |
| Number of Participants According to Metastasis Status | Relugolix | Non-metastatic prostate cancer | 338 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06462014/results